Vapaliximab Biosimilar – Anti-AOC3, VAP-1 mAb – Research Grade from ProteoGenix; catalogue PX-TA1197; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Vapaliximab Biosimilar, also known as Anti-AOC3 or VAP-1 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original drug Vapaliximab. This biosimilar is a promising therapeutic option for the treatment of various inflammatory and autoimmune diseases, as it targets a specific protein called AOC3. In this article, we will provide a scientific description of Vapaliximab Biosimilar in terms of its structure, activity, and potential applications.
Vapaliximab Biosimilar is a recombinant humanized monoclonal antibody that is produced using genetic engineering techniques. It is a protein molecule composed of two heavy chains and two light chains, connected by disulfide bonds. The heavy chains consist of constant and variable regions, while the light chains only have variable regions. The variable regions are responsible for binding to the target protein AOC3.
Vapaliximab Biosimilar is a highly specific antibody that targets the protein AOC3, also known as Vascular Adhesion Protein-1 (VAP-1). AOC3 is a cell surface enzyme that plays a crucial role in the inflammatory response and is involved in the development of various autoimmune diseases. By binding to AOC3, Vapaliximab Biosimilar blocks its activity and inhibits the recruitment of inflammatory cells to the site of inflammation.
Vapaliximab Biosimilar has been shown to have potent anti-inflammatory effects in preclinical studies. It has been found to reduce the production of pro-inflammatory cytokines and chemokines, as well as inhibit the adhesion and migration of immune cells. This makes it a promising therapeutic option for the treatment of a wide range of inflammatory and autoimmune diseases.
Vapaliximab Biosimilar has shown promising results in preclinical studies for the treatment of various inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. It has also been evaluated in clinical trials for the treatment of diabetic retinopathy, a condition characterized by inflammation and abnormal blood vessel growth in the retina.
In addition to its potential as a therapeutic agent, Vapaliximab Biosimilar can also be used as a research tool to study the role of AOC3 in various diseases. By blocking the activity of AOC3, researchers can gain a better understanding of its role in the inflammatory response and its potential as a therapeutic target.
In summary, Vapaliximab Biosimilar, also known as Anti-AOC3 or VAP-1 mAb, is a recombinant humanized monoclonal antibody that specifically targets the protein AOC3. It has shown potent anti-inflammatory effects in preclinical studies and has the potential to be used as a therapeutic agent for various inflammatory and autoimmune diseases. In addition, it can also serve as a valuable research tool for studying the role of AOC3 in disease. Further clinical studies are needed to fully evaluate the efficacy and safety of Vapaliximab Biosimilar in treating inflammatory and autoimmune conditions.
ProteoGenix catalogue number PX-TA1197. For research use only.
Target: Vapaliximab Biosimilar – Anti-AOC3, VAP-1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Vapaliximab Biosimilar – Anti-AOC3, VAP-1 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
